Health Care & Life Sciences » Pharmaceuticals | Horizon Pharma PLC

Horizon Pharma PLC | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
74
297
757
1,046
1,056
1,208
Cost of Goods Sold (COGS) incl. D&A
15
69
220
396
546
422
Gross Income
59
228
538
650
510
785
SG&A Expense
102
227
482
651
902
769
EBIT
43
1
-
1
392
16
Unusual Expense
96
257
78
146
1
56
Non Operating Income/Expense
1
10
41
6
7
43
Interest Expense
13
24
70
87
127
122
Pretax Income
150
270
133
228
513
119
Income Tax
1
6
172
61
103
45
Consolidated Net Income
149
264
40
167
411
74
Net Income
149
264
40
167
411
74
Net Income After Extraordinaries
149
264
40
167
411
74
Net Income Available to Common
149
264
40
167
411
74
EPS (Basic)
2.34
3.15
0.25
1.04
2.52
0.45
Basic Shares Outstanding
64
84
149
161
163
166
EPS (Diluted)
2.34
3.15
0.25
1.04
2.52
0.45
Diluted Shares Outstanding
64
84
156
161
163
166
EBITDA
34
35
194
221
109
291

About Horizon Pharma

View Profile
Address
Connaught House
Dublin Dublin 4
Ireland
Employees -
Website http://www.horizontherapeutics.com
Updated 07/08/2019
Horizon Pharma Plc engages in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo.

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.